Literature DB >> 19619521

Role of large-conductance Ca(2+) -activated potassium channels in adenosine A(1) receptor-mediated pharmacological preconditioning in H9c2 cells.

Laurice Fretwell1, John M Dickenson.   

Abstract

Large-conductance Ca(2+)-activated potassium channels, located on the inner mitochondrial membrane, have recently been implicated in cytoprotection. Therefore, the primary aim of this study was to determine the role of large-conductance Ca(2+)-activated potassium channels in adenosine A(1) receptor-induced pharmacological preconditioning in the rat embryonic cardiomyoblast-derived cell line H9c2. For pharmacological preconditioning, H9c2 cells were exposed to the adenosine A(1) receptor agonist N(6)-cyclopentyladenosine (100 nM) or the Ca(2+)-activated potassium channel opener NS1619 (10 microM) for 30 min prior to 6 h hypoxia (0.5% O(2)) in glucose-free and serum-free media. Where appropriate cells were treated (15 min) before pharmacological preconditioning with the Ca(2+)-activated potassium channels blockers paxilline (1 microM) or iberiotoxin (100 nM). Cell viability following 6 h hypoxia was assessed by monitoring lactate dehydrogenase (LDH) release and caspase-3 activation. Ca(2+)-activated potassium channel subunit protein expression and cell survival protein kinase (ERK1/2 and PKB/Akt) activation were assessed by Western blotting. The results demonstrate that the adenosine A(1) receptor is functionally expressed in H9c2 cells and when activated protects against hypoxia-induced LDH release and caspase-3 activation. Treatment with paxilline or iberiotoxin attenuated adenosine A(1) receptor and NS1619-induced pharmacological preconditioning. Large-conductance Ca(2+)-activated potassium channel alpha and beta4 protein subunits were detected in mitochondrial fractions isolated from H9c2 cells. NS1619 (10 microM) induced no significant changes in ERK1/2 or PKB phosphorylation. These results have shown for the first time that large-conductance Ca(2+)-activated potassium channels are involved in adenosine A(1) receptor-induced pharmacological preconditioning in a cell model system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19619521     DOI: 10.1016/j.ejphar.2009.07.008

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  The Slo(w) path to identifying the mitochondrial channels responsible for ischemic protection.

Authors:  Charles Owen Smith; Keith Nehrke; Paul S Brookes
Journal:  Biochem J       Date:  2017-06-09       Impact factor: 3.857

Review 2.  Preconditioning strategy in stem cell transplantation therapy.

Authors:  Shan Ping Yu; Zheng Wei; Ling Wei
Journal:  Transl Stroke Res       Date:  2013-02       Impact factor: 6.829

3.  Modulation of transglutaminase 2 activity in H9c2 cells by PKC and PKA signalling: a role for transglutaminase 2 in cytoprotection.

Authors:  Ibtesam Almami; John M Dickenson; Alan J Hargreaves; Philip L R Bonner
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

4.  A non-cardiomyocyte autonomous mechanism of cardioprotection involving the SLO1 BK channel.

Authors:  Andrew P Wojtovich; Sergiy M Nadtochiy; William R Urciuoli; Charles O Smith; Morten Grunnet; Keith Nehrke; Paul S Brookes
Journal:  PeerJ       Date:  2013-03-05       Impact factor: 2.984

Review 5.  BK channel activators and their therapeutic perspectives.

Authors:  Bo H Bentzen; Søren-Peter Olesen; Lars C B Rønn; Morten Grunnet
Journal:  Front Physiol       Date:  2014-10-09       Impact factor: 4.566

6.  Single-Channel Properties of the ROMK-Pore-Forming Subunit of the Mitochondrial ATP-Sensitive Potassium Channel.

Authors:  Michał Laskowski; Bartłomiej Augustynek; Piotr Bednarczyk; Monika Żochowska; Justyna Kalisz; Brian O'Rourke; Adam Szewczyk; Bogusz Kulawiak
Journal:  Int J Mol Sci       Date:  2019-10-25       Impact factor: 5.923

Review 7.  The immunomodulatory function of adenosine in sepsis.

Authors:  Teng Zhang; Li Yu-Jing; Tao Ma
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.